LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・ADMA Biologics Inc

ADMA Biologics Inc

Затворен

СекторЗдравеопазване

8.22 -2.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.18

Максимум

8.26

Ключови измерители
By Trading Economics
Приходи	-4.1M 45M
Продажби	-25M 114M
P/E Средно за сектора	12.324 49.701
EPS	0.17
Марж на печалбата	39.59
Служители	640
EBITDA	-13M 52M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+187.26% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-453M 1.9B
Предишно отваряне	10.83
Предишно затваряне	8.22

Настроения в новините

By Acuity

85%

15%

324 / 345 Класиране в Healthcare

ADMA Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.05.2026 г., 08:24 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25.05.2026 г., 21:22 ч. UTC

Печалби

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:01 ч. UTC

Пазарно говорене

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25.05.2026 г., 14:43 ч. UTC

Пазарно говорене

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25.05.2026 г., 14:15 ч. UTC

Пазарно говорене

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25.05.2026 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.05.2026 г., 12:58 ч. UTC

Пазарно говорене

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25.05.2026 г., 12:56 ч. UTC

Пазарно говорене

Печалби

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.05.2026 г., 12:34 ч. UTC

Пазарно говорене

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25.05.2026 г., 12:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero's Assets Look Strategic -- Market Talk

25.05.2026 г., 11:00 ч. UTC

Пазарно говорене

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25.05.2026 г., 10:19 ч. UTC

Пазарно говорене

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25.05.2026 г., 10:05 ч. UTC

Печалби

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25.05.2026 г., 10:04 ч. UTC

Печалби

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25.05.2026 г., 10:03 ч. UTC

Печалби

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25.05.2026 г., 10:02 ч. UTC

Печалби

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25.05.2026 г., 10:01 ч. UTC

Печалби

Tenaga Nasional 1Q Net Up 3.7% on Year

25.05.2026 г., 10:00 ч. UTC

Печалби

Tenaga Nasional 1Q Rev Up 6.6% on Year

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q EPS MYR0.1883

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Rev MYR17.1B

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Net MYR1.1B

25.05.2026 г., 09:38 ч. UTC

Пазарно говорене

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25.05.2026 г., 08:55 ч. UTC

Пазарно говорене

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

ADMA Biologics Inc Прогноза

Ценова цел

By TipRanks

187.26% нагоре

12-месечна прогноза

Среден 23.67 USD 187.26%

Висок 30 USD

Нисък 20 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за ADMA Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на ADMA Biologics Inc през последните 3 месеца.

Настроение

By Acuity

324 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.